Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer

REFERENCES

• Herbst, R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004, 59, 21–26.
   PubMed Web of Science ®Google Scholar
• Carpenter, G.; Cohen, S. Epidermal growth factor. Annu Rev Biochem 1979, 48, 193–216.
   Google Scholar
• Carpenter, G.; Cohen, S. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 1976, 71, 159–171.
   PubMed Web of Science ®Google Scholar
• Glover, K.Y.; Perez-Soler, R.; Papadimitradopoulou, V.A. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004, 31, 83–92.
   PubMed Web of Science ®Google Scholar
• Hunter, T.; Cooper, J.A. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981, 24, 741–752.
   PubMed Web of Science ®Google Scholar
• Vlahovic, G.; Crawford, J. Activation of tyrosine kinases in cancer. Oncologist 2003, 8, 531–538.
   PubMed Web of Science ®Google Scholar
• Veale, D.; Ashcroft, T.; Marsh, C.; Gibson, G.J.; Harris, A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987, 55, 513–516.
   PubMed Web of Science ®Google Scholar
• Sobol, R.E.; Astarita, R.W.; Hofeditz, C.; Masui, H.; Fairshter, R.; Royston, I.; Mendelsohn, J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987, 79, 403–407.
   PubMed Web of Science ®Google Scholar
• Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19,183–232.
   PubMed Web of Science ®Google Scholar
• Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A., Jr.; Di Maria, M.V.; Veve, R.; Bremmes, R.M.; Baron, A.E.; Zeng, C.; Franklin, W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21, 3798–3807.
   PubMed Web of Science ®Google Scholar
• Moscatello, D.K.; Holgado-Madruga, M.; Godwin, A.K.; Ramirez, G.; Gunn, G.; Zoltick, P.W.; Biegel, J.A.; Hayes, R.L.; Wong, A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55, 5536–5539.
   PubMed Web of Science ®Google Scholar
• Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402, 884–888.
   PubMed Web of Science ®Google Scholar
• Liu, D.; Aguirre Ghiso, J.; Estrada, Y.; Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1, 445–457.
   PubMed Web of Science ®Google Scholar
• El-Rayes, B.F.; LoRusso, P.M. Targeting the epidermal growth factor receptor. Br J Cancer 2004, 91, 418–424.
   PubMed Web of Science ®Google Scholar
• Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82,241–250.
   PubMed Web of Science ®Google Scholar
• Yarden, Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl. 4), S3–S8.
   PubMed Web of Science ®Google Scholar
• Oda, K.; Matsuoka, Y.; Funahashi, A.; Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005, 1, 2005.0010.
   PubMed Web of Science ®Google Scholar
• Lowenstein, E.J.; Daly, R.J.; Batzer, A.G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E.Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70, 431–442.
   PubMed Web of Science ®Google Scholar
• Nagai, Y.; Miyazawa, H.; Huqun, Tanaka, T.; Udagawa, K.; Kato, M.; Fukuyama, S.; Yokote, A.; Kobayashi, K.; Kanazawa, M.; Hagiwara, K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65, 7276–7282.
   PubMed Web of Science ®Google Scholar
• von Eyben, F.E. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 2006, 43, 291–323.
   PubMed Web of Science ®Google Scholar
• Hartl, M.; Bader, A.G.; Bister, K. Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 2003, 3, 41–55.
   PubMed Web of Science ®Google Scholar
• Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M.J.; Moyer, M.P.; Neveu, M.; Pollack, V.A.; Pustilnik, L.R.; Reynolds, M.M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57, 4838–4848.
   PubMed Web of Science ®Google Scholar
• Wu, X.; Fan, Z.; Masui, H.; Rosen, N.; Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995, 95, 1897–1905.
   PubMed Web of Science ®Google Scholar
• Wu, X.; Rubin, M.; Fan, Z.; DeBlasio, T.; Soos, T.; Koff, A.; Mendelsohn, J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12, 1397–1403.
   PubMed Web of Science ®Google Scholar
• Peng, D.; Fan, Z.; Lu, Y.; DeBlasio, T.; Scher, H.; Mendelsohn, J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996, 56, 3666–3669.
   PubMed Web of Science ®Google Scholar
• Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9, 667–676.
   PubMed Web of Science ®Google Scholar
• Bellacosa, A.; Chan, T.O.; Ahmed, N.N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17, 313–325.
   PubMed Web of Science ®Google Scholar
• Sordella, R.; Bell, D.W.; Haber, D.A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163–1167.
   PubMed Web of Science ®Google Scholar
• Tracy, S.; Mukohara, T.; Hansen, M.; Meyerson, M.; Johnson, B.E.; Janne, P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004, 64, 7241–7244.
   PubMed Web of Science ®Google Scholar
• Duronio, V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008, 415, 333–344.
   PubMed Web of Science ®Google Scholar
• Perry, J.E.; Grossmann, M.E.; Tindall, D.J. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998, 35, 117–124.
   PubMed Web of Science ®Google Scholar
• Wang, Q.; Greene, M.I. EGFR enhances survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 2005, 79, 100–107.
   PubMed Web of Science ®Google Scholar
• Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396, 580–584.
   PubMed Web of Science ®Google Scholar
• Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58, 5315–5320.
   PubMed Web of Science ®Google Scholar
• Carvalho, A.; Carmena, M.; Sambade, C.; Earnshaw, W.C.; Wheatley, S.P. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003, 116, 2987–2998.
   PubMed Web of Science ®Google Scholar
• Temme, A.; Rieger, M.; Reber, F.; Lindemann, D.; Weigle, B.; Diestelkoetter-Bachert, P.; Ehninger, G.; Tatsuka, M.; Terada, Y.; Rieber, E.P. Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 2003, 14, 78–92.
   PubMed Web of Science ®Google Scholar
• Uren, A.G.; Wong, L.; Pakusch, M.; Fowler, K.J.; Burrows, F.J.; Vaux, D.L.; Choo, K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000, 10, 1319–1328.
   PubMed Web of Science ®Google Scholar
• Kulik, G.; Klippel, A.; Weber, M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997, 17, 1595–1606.
   PubMed Web of Science ®Google Scholar
• Nagane, M.; Coufal, F.; Lin, H.; Bogler, O.; Cavenee, W.K.; Huang, H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996, 56, 5079–5086.
   PubMed Web of Science ®Google Scholar
• Karnes, W.E., Jr.; Weller, S.G.; Adjei, P.N.; Kottke, T.J.; Glenn, K.S.; Gores, G.J.; Kaufmann, S.H. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 1998, 114, 930–939.
   PubMed Web of Science ®Google Scholar
• Modjtahedi, H.; Affleck, K.; Stubberfield, C.; Dean, C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998, 13, 335–342.
   PubMed Web of Science ®Google Scholar
• Uckun, F.M.; Narla, R.K.; Jun, X.; Zeren, T.; Venkatachalam, T.; Waddick, K.G.; Rostostev, A.; Myers, D.E. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 1998, 4, 901–912.
   PubMed Web of Science ®Google Scholar
• He, Y.; Zeng, Q.; Drenning, S.D.; Melhem, M.F.; Tweardy, D.J.; Huang, L.; Grandis, J.R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998, 90, 1080–1087.
   PubMed Web of Science ®Google Scholar
• Shao, H.; Cheng, H.Y.; Cook, R.G.; Tweardy, D.J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003, 63, 3923–3930.
   PubMed Web of Science ®Google Scholar
• Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415–1421.
   PubMed Web of Science ®Google Scholar
• Goldman, C.K.; Kim, J.; Wong, W.L.; King, V.; Brock, T.; Gillespie, G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4, 121–133.
   PubMed Web of Science ®Google Scholar
• Folkman, J. Angiogenesis and its inhibitors. Important Adv Oncol 1985, 42–62.
   PubMedGoogle Scholar
• Grotendorst, G.R.; Soma, Y.; Takehara, K.; Charette, M. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989, 139, 617–623.
   PubMed Web of Science ®Google Scholar
• de Jong, J.S.; van Diest, P.J.; van der Valk, P.; Baak, J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 1998, 184, 44–52.
   PubMed Web of Science ®Google Scholar
• Petit, A.M.; Rak, J.; Hung, M.C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151, 1523–1530.
   PubMed Web of Science ®Google Scholar
• Rosen, E.M.; Goldberg, I.D. Protein factors which regulate cell motility. In Vitro Cell Dev Biol 1989, 25, 1079–1087.
   PubMed Web of Science ®Google Scholar
• Price, J.T.; Wilson, H.M.; Haites, N.E. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 1996, 32A, 1977–1982.
   PubMed Web of Science ®Google Scholar
• Shibata, T.; Kawano, T.; Nagayasu, H.; Okumura, K.; Arisue, M.; Hamada, J.; Takeichi, N.; Hosokawa, M. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 1996, 17, 168–175.
   PubMed Web of Science ®Google Scholar
• Verbeek, B.S.; Adriaansen-Slot, S.S.; Vroom, T.M.; Beckers, T.; Rijksen, G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998, 425, 145–150.
   PubMed Web of Science ®Google Scholar
• Turner, T.; Chen, P.; Goodly, L.J.; Wells, A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 1996, 14, 409– 418.
   PubMed Web of Science ®Google Scholar
• Watabe, T.; Yoshida, K.; Shindoh, M.; Kaya, M.; Fujikawa, K.; Sato, H.; Seiki, M.; Ishii, S.; Fujinaga, K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998, 77, 128–137.
   PubMed Web of Science ®Google Scholar
• Yasui, W.; Sumiyoshi, H.; Hata, J.; Kameda, T.; Ochiai, A.; Ito, H.; Tahara, E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988, 48, 137–141.
   PubMed Web of Science ®Google Scholar
• Yonemura, Y.; Takamura, H.; Ninomiya, I.; Fushida, S.; Tsugawa, K.; Kaji, M.; Nakai, Y.; Ohoyama, S.; Yamaguchi, A.; Miyazaki, I. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992, 49, 157–161.
   PubMed Web of Science ®Google Scholar
• Prakash, I.; Mathur, R.P.; Kar, P.; Ranga, S.; Talib, V.H. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J Pathol Microbiol 1997, 40, 481–490.
   PubMedGoogle Scholar
• Parker, C.; Roseman, B.J.; Bucana, C.D.; Tsan, R.; Radinsky, R. Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J Histochem Cytochem 1998, 46, 595–602.
   PubMed Web of Science ®Google Scholar
• Radinsky, R.; Risin, S.; Fan, D.; Dong, Z.; Bielenberg, D.; Bucana, C.D.; Fidler, I.J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995, 1, 19–31.
   PubMed Web of Science ®Google Scholar
• Kurie, J.M.; Shin, H.J.; Lee, J.S.; Morice, R.C.; Ro, J.Y.; Lippman, S.M.; Hittelman, W.N.; Yu, R.; Lee, J.J.; Hong, W.K.. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996, 2, 1787–1793.
   PubMed Web of Science ®Google Scholar
• Franklin, W.A.; Veve, R., Hirsch, F.R., Helfrich, B.A., Bunn, P.A., Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29, 3–14.
   PubMed Web of Science ®Google Scholar
• Bunn, P.A., Jr.; Franklin, W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002, 29, 38–44.
   PubMed Web of Science ®Google Scholar
• Fujino, S.; Enokibori, T.; Tezuka, N.; Asada, Y.; Inoue, S.; Kato, H.; Mori, A. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996, 32A, 2070–2074.
   PubMed Web of Science ®Google Scholar
• Pavelic, K.; Banjac, Z.; Pavelic, J.; Spaventi, S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993, 13, 1133–1137.
   PubMed Web of Science ®Google Scholar
• Veale, D.; Kerr, N.; Gibson, G.J.; Kelly, P.J.; Harris, A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68, 162–165.
   PubMed Web of Science ®Google Scholar
• Volm, M.; Rittgen, W.; Drings, P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998, 77,663–669.
   PubMed Web of Science ®Google Scholar
• Brabender, J.; Danenberg, K.D.; Metzger, R.; Schneider, P.M.; Park, J.; Salonga, D.; Holscher, A.H.; Danenberg, P.V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7, 1850–1855.
   PubMed Web of Science ®Google Scholar
• Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P.W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3, 515–522.
   PubMed Web of Science ®Google Scholar
• Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J.A.; Wolf, M.K.; Krebs, A.D.; Averbuch, S.D.; Ochs, J.S.; Grous, J.; Fandi, A.; Johnson, D.H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 2004, 22, 785–794.
   PubMed Web of Science ®Google Scholar
• Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R.B.; Schiller, J.H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J.S.; Averbuch, S.D.; Wolf, M.K.; Rennie, P.; Fandi, A.; Johnson, D.H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 2004, 22, 777–784.
   PubMed Web of Science ®Google Scholar
• Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; Brannigan, B.W.; Sgroi, D.C.; Muir, B.; Riemenschneider, M.J.; Iacona, R.B.; Krebs, A.D.; Johnson, D.H.; Giaccone, G.; Herbst, R.S.; Manegold, C.; Fukuoka, M.; Kris, M.G.; Baselga, J.; Ochs, J.S.; Haber, D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23, 8081–8092.
   PubMed Web of Science ®Google Scholar
• Nakamura, H.; Kawasaki, N.; Taguchi, M.; Kabasawa, K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61, 140–145.
   PubMed Web of Science ®Google Scholar
• Dubey, S.; Stephenson, P.; Levy, D.E.; Miller, J.A.; Keller, S.M.; Schiller, J.H.; Johnson, D.H.; Kolesar, J.M. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006, 1, 406–412.
   PubMed Web of Science ®Google Scholar
• Hirsch, F.R. EGFR: a prognostic and/or a predictive marker? J Thorac Oncol 2006, 1, 395–397.
   PubMed Web of Science ®Google Scholar
• Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500.
   PubMed Web of Science ®Google Scholar
• Sasaki, H.; Shimizu, S.; Endo, K.; Takada, M.; Kawahara, M.; Tanaka, H.; Matsumura, A.; Iuchi, K.; Haneda, H.; Suzuki, E.; Kobayashi, Y.; Yano, M.; Fujii, Y. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118, 180–184.
   PubMed Web of Science ®Google Scholar
• Ganti, A.K.; Potti, A. Epidermal growth factor inhibition in solid tumours. Expert Opin Biol Ther 2005, 5, 1165–1174.
   PubMed Web of Science ®Google Scholar
• Sato, J.D.; Kawamoto, T.; Le, A.D.; Mendelsohn, J.; Polikoff, J.; Sato, G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1, 511–529.
   PubMedGoogle Scholar
• Lichtner, R.B.; Menrad, A.; Sommer, A.; Klar, U.; Schneider, M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61, 5790–5795.
   PubMed Web of Science ®Google Scholar
• Yamazaki, H.; Kijima, H.; Ohnishi, Y.; Abe, Y.; Oshika, Y.; Tsuchida, T.; Tokunaga, T.; Tsugu, A.; Ueyama, Y.; Tamaoki, N.; Nakamura, M. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 1998, 90, 581–587.
   PubMed Web of Science ®Google Scholar
• Ciardiello, F.; Caputo, R.; Troiani, T.; Borriello, G.; Kandimalla, E.R.; Agrawal, S.; Mendelsohn, J.; Bianco, A.R.; Tortora, G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001, 93, 172–178.
   PubMed Web of Science ®Google Scholar
• Masui, H.; Moroyama, T.; Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1986, 46, 5592–5598.
   PubMed Web of Science ®Google Scholar
• Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8, 3–9.
   PubMed Web of Science ®Google Scholar
• Yang, X.D.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G.; Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59, 1236–1243.
   PubMed Web of Science ®Google Scholar
• Fan, Z.; Baselga, J.; Masui, H.; Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53, 4637–4642.
   PubMed Web of Science ®Google Scholar
• Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6, 701–708.
   PubMed Web of Science ®Google Scholar
• Sirotnak, FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003, 30, 12–20.
   PubMed Web of Science ®Google Scholar
• Judde, J.G.; Rebucci, M.; Vogt, N.; de Cremoux, P.; Livartowski, A.; Chapelier, A.; Tran-Perennou, C.; Boye, K.; Defrance, R.; Poupon, M.F.; Bras-Goncalves, R.A. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007, 120, 1579–1590.
   Google Scholar
• Baselga, J.; Averbuch, S.D. ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000, 60(Suppl. 1), 33–40; discussion 41–32.
   PubMedGoogle Scholar
• Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6, 2053–2063.
   PubMed Web of Science ®Google Scholar
• Sirotnak, F.M.; Zakowski, M.F.; Miller, V.A.; Scher, H.I.; Kris, M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6, 4885–4892.
   PubMed Web of Science ®Google Scholar
• Higgins, B.; Kolinsky, K.; Smith, M.; Beck, G.; Rashed, M.; Adames, V.; Linn, M.; Wheeldon, E.; Gand, L.; Birnboeck, H.; Hoffmann, G. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004, 15, 503–512.
   PubMed Web of Science ®Google Scholar
• Hidalgo, M. Erlotinib: preclinical investigations. Oncology (Williston Park) 2003, 17, 11–16.
   PubMedGoogle Scholar
• Bianco, C.; Tortora, G.; Bianco, R.; Caputo, R.; Veneziani, B.M.; Caputo, R.; Damiano, V.; Troiani, T.; Fontanini, G.; Raben, D.; Pepe, S.; Bianco, A.R.; Ciardiello, F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8, 3250–3258.
   PubMed Web of Science ®Google Scholar
• Huang, S.M.; Li, J.; Armstrong, E.A.; Harari, P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002, 62, 4300–4306.
   PubMed Web of Science ®Google Scholar
• Hanna, N.; Lilenbaum, R.; Ansari, R.; Lynch, T.; Govindan, R.; Janne, P.A.; Bonomi, P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24, 5253–5258.
   PubMed Web of Science ®Google Scholar
• Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B.C.; Pfeifer, W.; O’Byrne, K.J.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M.R.; Ellis, P.A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19, 362–369.
   PubMed Web of Science ®Google Scholar
• Robert, F.; Blumenschein, G.; Herbst, R.S.; Fossella, F.V.; Tseng, J.; Saleh, M.N.; Needle, M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 9089–9096.
   PubMed Web of Science ®Google Scholar
• Thienelt, C.D.; Bunn, P.A., Jr.; Hanna, N.; Rosenberg, A.; Needle, M.N.; Long, M.E.; Gustafson, D.L.; Kelly, K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23, 8786–8793.
   PubMed Web of Science ®Google Scholar
• Belani, C.P.; Ramalingam, S.; Schreeder, M.; Steis, R.; Guidice, R.; Marshland, T.; Butler, B. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2007, 25, 7643.
   Google Scholar
• Kim, E.S.; Mauer, A.M.; Fossella, F.V.; Jamison, T.A.; Kies, M.S.; Pisters, K.M.; Glisson, B.S.; Blumenschein Jr GR; Zinner, R.G.; Windt, P.; Liu, D.; Khuri, F.; Dicke, K.; Needle, M.; Vokes, E.E.; Hong, W.K.; Herbst, R.S. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21, 293a.
   Google Scholar
• Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; Roh, J.K.; Bajetta, E.; O’Byrne, K.; de Marinis, F.; Eberhardt, W.; Goddemeier, T.; Emig, M.; Gatzemeier, U. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008, 26, 3.
   Google Scholar
• Crawford, J.; Sandler, A.B.; Hammond, L.A.; Schiller, J.; Belani, C.; Kozloff, M.; Johnson, D.; Fleishman, A.; Lee, S.; Takeshita, K. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2004, 22, 7083-.
   Google Scholar
• Blumenschein, G.; Sandler, A.; O’Rourke, T.; McGreivy, J.; Sun, Y.-N.; Ye, Y.; Parson, M.; Stephenson, J.J. Safety and pharmaco- kinetics (PK) of AMG 706 with carboplatin/paclitaxel (C/P) and/or panitumumab for the treatment of patients with advanced non- small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2, S469.
   Web of Science ®Google Scholar
• Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J., Jr.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003, 290, 2149–2158.
   PubMed Web of Science ®Google Scholar
• Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003, 21, 2237–2246.
   PubMed Web of Science ®Google Scholar
• Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527–1537.
   PubMed Web of Science ®Google Scholar
• Mok, T.; Wu, Y.-L.; Thongprasert, S.; Yang, C.-H.; Chu, D.; Saijo, N.; Jiang, H.; Watkins, C.; Armour, A.; Fukuoka, M. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008, 19, viii1–viii4.
   Google Scholar
• Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.-L.; Li, L.-Y.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y.; Liao, M.-L.; Østerlind, K.; Reck, M.; Armour, A.A.; Shepherd, F.A.; Lippman, S.M.; Douillard, J.-Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet 2008, 372, 1809–1818.
   PubMed Web of Science ®Google Scholar
• Crino, L.; Cappuzzo, F.; Zatloukal, P.; Reck, M.; Pesek, M.; Thompson, J.C.; Ford, H.E.R.; Hirsch, F.R.; Varella-Garcia, M.; Ghiorghiu, S.; Duffield, E.L.; Armour, A.A.; Speake, G.; Cullen, M. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26, 4253–4260.
   PubMed Web of Science ®Google Scholar
• Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353, 123–132.
   PubMed Web of Science ®Google Scholar
• Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz, J.; Manikhas, G.M.; Von Pawel, J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007, 25, 1545–1552.
   PubMed Web of Science ®Google Scholar
• Herbst, R.S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; Kris, M.G.; Tran, H.T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D.H.; Miller, V.A. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 5892–5899.
   PubMed Web of Science ®Google Scholar
• Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350, 2129–2139.
   PubMed Web of Science ®Google Scholar
• Kubo, A.; Nakagawa, K.; Kashii, T.; Hirashima, T.; Sasaki, J.; Tanaka, K.; Sato, S.; Kurata, T.; Tamura, K.; Fukuoka, M. Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: results of West Japan thoracic oncology group trial (WJTOG0203A). J Thoracic Oncol 2007, 2, S323.
   Web of Science ®Google Scholar
• Toyooka, S.; Takano, T.; Kosaka, T.; Ichihara, S.; Fujiwara, Y.; Hotta, K.; Soh, J.; Kiura, K.; Yatabe, Y.; Ohe, Y.; Mitsudomi, T.; Date, H. The impact of EGFR mutation and smoking status on non-smallcell lung cancer patients treated with geftinib. J Thorac Oncol 2007, 2, S324.
   Web of Science ®Google Scholar
• Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A., Jr.; Franklin, W.A.; Dziadziuszko, R.; Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J.R.; Ciuleanu, T.; von Pawel, J.; Watkins, C.; Flannery, A.; Ellison, G.; Donald, E.; Knight, L.; Parums, D.; Botwood, N.; Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24, 5034–5042.
   PubMed Web of Science ®Google Scholar
• Hirsch, F.R.; Varella-Garcia, M.; Cappuzzo, F.; McCoy, J.; Bemis, L.; Xavier, A.C.; Dziadziuszko, R.; Gumerlock, P.; Chansky, K.; West, H.; Gazdar, A.F.; Crino, L.; Gandara, D.R.; Franklin, W.A.; Bunn, P.A., Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18, 752–760.
   PubMed Web of Science ®Google Scholar
• Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005, 353, 133–144.
   PubMed Web of Science ®Google Scholar
• Han, S.W.; Kim, T.Y.; Hwang, P.G.; Jeong, S.; Kim, J.; Choi, I.S.; Oh, D.Y.; Kim, J.H.; Kim, D.W.; Chung, D.H.; Im, S.A.; Kim, Y.T.; Lee, J.S.; Heo, D.S.; Bang, Y.J.; Kim, N.K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23, 2493–2501.
   PubMed Web of Science ®Google Scholar
• Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23,2513–2520.
   PubMed Web of Science ®Google Scholar
• Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I.; Kunitoh, H.; Shibata, T.; Sakiyama, T.; Yoshida, T.; Tamura, T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23, 6829– 6837.
   PubMed Web of Science ®Google Scholar
• Liu, G.; Gurubhagavatula, S.; Zhou, W.; Wang, Z.; Yeap, B.Y.; Asomaning, K.; Su, L.; Heist, R.; Lynch, T.J.; Christiani, D.C. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008, 8, 129–138.
   PubMed Web of Science ®Google Scholar
• Potti, A.; Dressman, H.K.; Bild, A.; Riedel, R.F.; Chan, G.; Sayer, R.; Cragun, J.; Cottrill, H.; Kelley, M.J.; Petersen, R.; Harpole, D.; Marks, J.; Berchuck, A.; Ginsburg, G.S.; Febbo, P.; Lancaster, J.; Nevins, J.R. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12, 1294–1300.
   PubMed Web of Science ®Google Scholar
• Eberhard, D.A.; Giaccone, G.; Johnson, B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26, 983–994.
   PubMed Web of Science ®Google Scholar
• Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Janne, P.A.; Joshi, V.A.; McCollum, D.; Evans, T.L.; Muzikansky, A.; Kuhlmann, G.L.; Han, M.; Goldberg, J.S.; Settleman, J.; Iafrate, A.J.; Engelman, J.A.; Haber, D.A.; Johnson, B.E.; Lynch, T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26, 2442–2449.
   PubMed Web of Science ®Google Scholar
• Cappuzzo, F.; Finocchiaro, G.; Metro, G.; Bartolini, S.; Magrini, E.; Cancellieri, A.; Trisolini, R.; Castaldini, L.; Tallini, G.; Crino, L. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 2006, 58, 31–45.
   PubMed Web of Science ®Google Scholar
• Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23, 2445–2459.
   PubMed Web of Science ®Google Scholar
• Wang, S.E.; Narasanna, A.; Perez-Torres, M.; Xiang, B.; Wu, F.Y.; Yang, S.; Carpenter, G.; Gazdar, A.F.; Muthuswamy, S.K.; Arteaga, C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10, 25–38.
   PubMed Web of Science ®Google Scholar
• Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Hwang, P.G.; Im, S.A.; Lee, K.H.; Kim, J.H.; Kim, D.W.; Heo, D.S.; Kim, N.K.; Chung, D.H.; Bang, Y.J. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12, 2538–2544.
   PubMed Web of Science ®Google Scholar
• Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O’Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359, 1757–1765.
   PubMed Web of Science ®Google Scholar
• Guix, M.; Faber, A.C.; Wang, S.E.; Olivares, M.G.; Song, Y.; Qu, S.; Rinehart, C.; Seidel, B.; Yee, D.; Arteaga, C.L.; Engelman, J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118, 2609–2619.
   PubMed Web of Science ®Google Scholar
• Morgillo, F.; Woo, J.K.; Kim, E.S.; Hong, W.K.; Lee, H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66, 10100–10111.
   PubMed Web of Science ®Google Scholar
• Morgillo, F.; Kim, W.Y.; Kim, E.S.; Ciardiello, F.; Hong, W.K.; Lee, H.Y. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13, 2795–2803.
   PubMed Web of Science ®Google Scholar
• Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039–1043.
   PubMed Web of Science ®Google Scholar
• Maruyama, R.; Nishiwaki, Y.; Tamura, T.; Yamamoto, N.; Tsuboi, M.; Nakagawa, K.; Shinkai, T.; Negoro, S.; Imamura, F.; Eguchi, K.; Takeda, K.; Inoue, A.; Tomii, K.; Harada, M.; Masuda, N.; Jiang, H.; Itoh, Y.; Ichinose, Y.; Saijo, N.; Fukuoka, M. Phase III study, V-15–32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26, 4244–4252.
   PubMed Web of Science ®Google Scholar